2'-amino-4'-fluoroacetanilide | 22380-13-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2'-amino-4'-fluoroacetanilide
• 英文别名: N-(2-Amino-4-fluorophenyl)acetamide
• CAS: 22380-13-8
• 化学式: C₈H₉FN₂O
• 分子量: 168.171
• InChiKey: LHGGVNQTVVGQJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2'-amino-4'-fluoroacetanilide 在 盐酸 作用下， 以 水 为溶剂， 反应 12.0h， 以1.15 g的产率得到4-氟-1,2-苯二胺
  参考文献：
  名称：

  一种4-氟取代芳基胺类化合物及其合成方法

  摘要：

  本发明公开了一种4‑氟取代芳基胺类化合物的合成方法，包括以下步骤：1)以酰基保护的苯基羟胺为底物，在极性溶剂中，以磺酰氟为氟源，在碱性条件下生成4‑氟取代苯胺类化合物；2)在稀酸性条件下或者Pd催化氢化进行脱保护基团，得到所述4‑氟取代芳基胺类化合物。本发明合成的4‑氟取代的苯胺类化合物，由于氟原子引入极大程度上增加其亲脂性，因此能广泛用于含氟药物、农药以及染料中间体的制备；同时，本发明采用的原料均为工业化产品，价廉易得，具有市售；通过本发明制得的4‑氟芳基苯胺收率高，能够以大于90％的收率得到纯度≥99％的产物；本发明操作简单，成本低廉的工艺十分适用于工业化，能够广泛推广使用。

  公开号：

  CN113416139B
• 作为产物：
  描述：

  4-氟-2-硝基乙酰苯胺 在 palladium on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 生成 2'-amino-4'-fluoroacetanilide
  参考文献：
  名称：

  Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome

  摘要：

  Disease-modifying therapies are needed for Fragile X Syndrome (FXS), as at present there are no effective treatments or cures. Herein, we report on a tetrahydroquinoline-based selective histone deacetylase 6 (HDAC6) inhibitor SW-100, its pharmacological and ADMET properties, and its ability to improve upon memory performance in a mouse model of FXS, Fmr1-1- mice. This small molecule demonstrates good brain penetrance, low-nanomolar potency for the inhibition of HDAC6 (IC50 = 2.3 nM), with at least a thousand-fold selectivity over all other class I, II, and IV HDAC isoforms. Moreover, through its inhibition of the alpha-tubulin deacetylase domain of HDAC6 (CD2), in cells SW-100 upregulates alpha-tubulin acetylation with no effect on histone acetylation and selectively restores the impaired acetylated alpha-tubulin levels in the hippocampus of Fmr1(-/-) mice. Lastly, SW-100 ameliorates several memory and learning impairments in Fmr1(-/-) mice, thus modeling the intellectual deficiencies associated with FXS, and hence providing a strong rationale for pursuing HDAC6-based therapies for the treatment of this rare disease.

  DOI：

  10.1021/acschemneuro.8b00600

文献信息

• Ahmad, Arshad; Dunbar, Linda J.; Green, Iain G., Journal of the Chemical Society. Perkin transactions I, 1994, # 19, p. 2751 - 2758
  作者：Ahmad, Arshad、Dunbar, Linda J.、Green, Iain G.、Harvey, Ian W.、Shepherd, Thomas、et al.

  DOI：——

  日期：——
• Syntheses and Properties of 1-Methyl-3-phenylaminobenzimidazolium Salts, Models of DNA Adducts of N7-Arylaminodeoxyguanosinium Salt
  作者：Toyo Kaiya、Tomoko Fujiwara、Kohfuku Kohda

  DOI：10.1021/tx0000724

  日期：2000.10.1

  When arylaminating carcinogens are administered to cells, they mainly generate the C8-arylamino-2'-deoxyguanosine adduct in DNA. A mechanism for this was proposed in which N7-arylaminated 2'-deoxyguanosine acts as an intermediate; however, it remained unclear whether this is actually the case. To elucidate the mechanisms involved in the generation of this adduct, a series of 5-substituted 1-methylbenzimidazole derivatives were used as models of the imidazole moiety of 2'-deoxyguanosine. Syntheses of a series of 5-substituted (CH3, H, F, CF3, or NO2) 1-methyl-3-phenylaminobenzimidazolium salts (7) and their related compounds were carried out, and the chemical characteristics of these products were examined. Keating compound 7 at 80 degreesC for 48 h in H2O/MeOH provided 5-substituted 1-methyl-2-oxo-2,3-dihydrobenzimidazoles but only when this compound contained a CF3 or NO2 substituent. Compound 7 decomposed in alkaline media, and its rate of decomposition increased when this compound had a stronger electron-withdrawing substituent. The product obtained under these conditions was 4-substituted N-1-methyl-2-phenylazoaniline. On the other hand, when 1-methyl-3-(4-nitrophenylamino)benzimidazolium salt was treated under the same conditions as described above, it generated, a demethylated product, 1-(4-nitrophenylamino)benzimidazole, when heated in H2O/MeOH and N-1-formyl-N-1-methyl-2-phenylazoaniline when treated in alkaline media. When the chemical characteristics of 3-phenylamino and 3-amino groups were compared using 3-substituted 1-methyl-5-(trifluoromethyl)benzimidazole the 3-phenylamino derivative was found to be more reactive.
• IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY
  申请人：THE GENERAL HOSPITAL CORPORATION

  公开号：US20210030899A1

  公开（公告）日：2021-02-04

  Disclosed herein are histone deacetylase imaging agents for positron emission tomography and related imaging methods using the histone deacetylase imaging agents. The histone deacetylase imaging agents may be a compound of formula (I): wherein R 1 is a moiety including a positron emitter; R 2 represents hydrogen, or substituted or unsubstituted alkyl, or substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and n is an integer selected from 0 or 1. In one version of the compound of formula (I), R 1 is a moiety including an adamantyl group.
• 一种4-氟取代芳基胺类化合物及其合成方法
  申请人：江苏笃行致远新材料科技有限公司

  公开号：CN113416139B

  公开（公告）日：2022-06-03

  本发明公开了一种4‑氟取代芳基胺类化合物的合成方法，包括以下步骤：1)以酰基保护的苯基羟胺为底物，在极性溶剂中，以磺酰氟为氟源，在碱性条件下生成4‑氟取代苯胺类化合物；2)在稀酸性条件下或者Pd催化氢化进行脱保护基团，得到所述4‑氟取代芳基胺类化合物。本发明合成的4‑氟取代的苯胺类化合物，由于氟原子引入极大程度上增加其亲脂性，因此能广泛用于含氟药物、农药以及染料中间体的制备；同时，本发明采用的原料均为工业化产品，价廉易得，具有市售；通过本发明制得的4‑氟芳基苯胺收率高，能够以大于90％的收率得到纯度≥99％的产物；本发明操作简单，成本低廉的工艺十分适用于工业化，能够广泛推广使用。
• Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome
  作者：Alan P. Kozikowski、Sida Shen、Marta Pardo、Maurício T. Tavares、Dora Szarics、Veronick Benoy、Chad A. Zimprich、Zsófia Kutil、Guiping Zhang、Cyril Bařinka、Matthew B. Robers、Ludo Van Den Bosch、James H. Eubanks、Richard S. Jope

  DOI：10.1021/acschemneuro.8b00600

  日期：2019.3.20

  Disease-modifying therapies are needed for Fragile X Syndrome (FXS), as at present there are no effective treatments or cures. Herein, we report on a tetrahydroquinoline-based selective histone deacetylase 6 (HDAC6) inhibitor SW-100, its pharmacological and ADMET properties, and its ability to improve upon memory performance in a mouse model of FXS, Fmr1-1- mice. This small molecule demonstrates good brain penetrance, low-nanomolar potency for the inhibition of HDAC6 (IC50 = 2.3 nM), with at least a thousand-fold selectivity over all other class I, II, and IV HDAC isoforms. Moreover, through its inhibition of the alpha-tubulin deacetylase domain of HDAC6 (CD2), in cells SW-100 upregulates alpha-tubulin acetylation with no effect on histone acetylation and selectively restores the impaired acetylated alpha-tubulin levels in the hippocampus of Fmr1(-/-) mice. Lastly, SW-100 ameliorates several memory and learning impairments in Fmr1(-/-) mice, thus modeling the intellectual deficiencies associated with FXS, and hence providing a strong rationale for pursuing HDAC6-based therapies for the treatment of this rare disease.